press releases

home > press releases
    • 2011
    • 2010
    • 2009
    • 2008
    • 2007
    • 2006
    • Archives >>
Dec 3 Addex and Merck & Co. Collaborate to Develop Drugs for Parkinson’s Disease
Nov 29 Addex Pharmaceuticals Confirms Extension of Major Shareholder Lock-up
Oct 29 Addex Presents ADX10059 GERD Data at Conference
Oct 1 ADX10061 Smoking Cessation Data
Aug 17 Addex Pharmaceuticals appoints Head of ADME/PK
Jul 25 Addex Pharmaceuticals First Half 2007 Financial Results
Jul 18 Addex First Half 2007 Financial Results Next Wednesday
May 21 Addex Prices IPO Shares at CHF73, raises CHF137 million
May 16 Addex appoints Head of IR and Communications
May 9 Addex Launches IPO on SWX Swiss Exchange
Apr 23 Addex Pharmaceuticals Plans IPO on SWX Swiss Exchange
Apr 20 Addex reports positive results in Phase IIa clinical trial with ADX10059 in Migraine
Apr 17 Addex achieves statistically significant outcome in Phase IIa clinical trial with ADX10059 in Gastro-Esophageal Reflux Disease
Apr 10 Addex initiates Phase I trials on ADX48621, a novel compound for treatment of Depression, Anxiety Disorder and Pain
Jan 24 Addex starts Phase IIa Proof of Concept Study on ADX10061 for Smoking Cessation

© 2012, ADDEX Pharmaceuticals